Morgens Waterfall Vintiadis & Co’s Heron Therapeutics HRTX Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-50,000	Closed	-$1.18M	–	41
2019 Q4	$1.18M	Buy	50,000 +11,000	+28%	+$243K	0.8%	35
2019 Q3	$722K	Hold	39,000	–	–	0.55%	39
2019 Q2	$725K	Hold	39,000	–	–	0.5%	40
2019 Q1	$953K	Hold	39,000	–	–	0.68%	37
2018 Q4	$1.01M	Hold	39,000	–	–	0.9%	38
2018 Q3	$1.23M	Hold	39,000	–	–	0.81%	37
2018 Q2	$1.51M	Buy	+39,000	New	+$1.24M	1.07%	28

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's HRTX Position: Q1 2020 in Review

Morgens Waterfall Vintiadis & Co sold out of Heron Therapeutics (HRTX) in Q1 2020, closing a stake of 50,000 shares — an estimated $1.18M sold.

Morgens Waterfall Vintiadis & Co first reported a position in HRTX in Q2 2018 and held it in 7 quarters. The position peaked at $1.51M in Q2 2018. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2020.

Morgens Waterfall Vintiadis & Co reported no remaining Heron Therapeutics position as of Q1 2020 after selling out during the quarter.
Morgens Waterfall Vintiadis & Co sold 50,000 Heron Therapeutics shares in Q1 2020, an estimated $1.18M.
Morgens Waterfall Vintiadis & Co first reported a position in Heron Therapeutics in Q2 2018 and held it in 7 quarters.
Morgens Waterfall Vintiadis & Co's Heron Therapeutics position peaked at $1.51M in Q2 2018.
193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2020.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q1 2020, filed 15 May 2020.